Welcome to Arrien Pharmaceuticals

Arrien Pharmaceuticals is a clinical stage drug discovery company focused on developing small molecules targeting protein kinase signaling, nuclear hormone receptor and immuno-oncology/checkpoint pathway targets for treating human cancers, autoimmune and neurodegenerative diseases.
The company successfully applied its proprietary platform "FIELDS" technology and discovered two clinical candidates and others in development:

  • ARN-6039 (currently known as BOS-172767), an orally available, selective small molecule inhibitor of ROR-γt (retinoic acid-related orphan nuclear hormone receptor gamma-t) being investigated in a Phase 1 clinical trials. The progress of ARN-6039 into Phase 1 development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. ARN-6039 was partnered with Boston Pharmaceuticals in 2017. A Phase 2 clinical POC studies in psoriasis and other autoimmune indications planed for Q3 2019. Our partner Boston Pharmaceuticals advancing several of their compounds in clinical trials that were the outcome of discovery collaborations and the responsibility for developing ARN-6039/BOS-172767 is with our partner.
  • ARN-3261, an orally available small molecule inhibitor of SIK2 (Salt Inducible Kinase 2) to be investigated in a Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors (TNBC, DLBCL & Prostate) and AML cancers. An IND being approved to initiate the Phase 1a/1b trials beginning of Q1 2019.
  • ARN-0953, an orally available, highly selective small molecule inhibitor of the MELK (Maternal Embryonic Leucine Zipper Kinase) and FLT3/CD135 (FMS like Tyrosine Kinase 3) specific kinases. ARN-0953 currently in IND enabling studies and to be investigated in Phase 1 clinical trials for AML and other solid tumors (TNBC, GBM & Lung cancers) in Q4 2019.
  • ARN-0894, an orally available, small molecule agonist of stimulatory checkpoint pathway targets responsible for costimulatory signals. Several agonist mAbs have been developed to engage with these checkpoint pathway targets and ARN-0894 currently in pre-clinicals stage of development. ARN-0894 discovered to potentially enhance the anti-tumor immunity though co-stimulatory mechanism. IND enabling studies to follow the initiation of Phase 1 clinical trials in Q3 2020.

Arrien Pharmaceuticals competitive and unique drug discovery and development approaches coupled with experienced scientific, clinical and business team who are expertise in multidisciplinary areas of kinase signaling, nuclear hormone receptor and checkpoint pathways and technology has been the key to company's success since its incorporation in 2011.

Read More..

Latest News

  • 03August
    2018

    Salt Lake City:
    Arrien Pharmaceuticals Management participates presenting Biocentury, The 25th Annual “News Maker in the Biotech Industry, September 7, 2018, New York City.
    Read more..

  • 05June
    2018

    Salt Lake City:
    Arrien Pharmaceuticals Management participates in Bio International Conference Boston, June 5-7, 2018.
    Read more..

  • 09February
    2018

    Salt Lake City:
    Arrien Pharmaceuticals Management participates in American Academy of Dermatology (AAD) Annual Meeting in San Diego, Calif., on Feb. 16-20, 2018.
    Read more..

  • 08January
    2018

    Salt Lake City:
    Arrien Pharmaceuticals management participates in 36th annual J. P. Morgan Health Care Conference | January 8-11, 2018 at the Westin in San Francisco, California, USA.
    Read more..

  • 28June
    2017

    Salt Lake City:
    Arrien Pharmaceuticals announces a worldwide license agreement for ARN-6039, a clinical stage oral ROR-?t inverse agonist for the treatment of psoriasis and potentially other autoimmune disorders.
    Read more..

  • 21February
    2017

    Salt Lake City:
    Arrien Pharmaceuticals pleased to announce that the American Association for Cancer Research (AACR) Selection Committee has accepted the Latte-Breaking Abstract titled 'Discovery of ARN-3261 as a Potent, Selective, Orally Available SIK2 Inhibitor for Treating Ovarian, Endometrial, Primary Peritoneal, Fallopian tube, and Triple Negative Breast Cancers' for presentation at the AACR Annual Meeting 2017 to be held in Washington, DC on April 1-5, 2017.
    Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
    Session Date and Time: Wednesday Apr 5, 2017 8:00 AM - 12:00 PM
    Session Location: Poster Section 34
    Poster Number: 4
    Abstract Number: LB-296
    http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105#.WKu1gfkrJHY

  • 11January
    2017

    Salt Lake City:
    Arrien Pharmaceuticals Management to participate in 2017 AAD (American Academy of Dermatology) Annual Meeting on March 03-07, 2017 in Orlando, Florida.
    Read More..

More News

Our Pipeline

Arrien Pharmaceuticals is focused on the drug discovery and development of innovative targeted therapeutics for the treatment of human cancers, autoimmune and neurodegenerative diseases.

Therapeutic Areas

Oncology Programs

Arrien Pharmaceuticals is pursuing several clinically relevant druggable targets particularly kinases, stimulatory and inhibitory immune checkpoint regulators with small molecules for the treatment of different cancers. The lead investigational agents; ARN-3261, ARN-0953 and ARN-0894 that are currently in various stages of development...

Other Programes

Arrien Pharmaceutical has discovered and advanced the development of small molecule antagonist ARN-6039 targeting Retinoic acid-related orphan nuclear receptor gt (RORgt)/RORg. RORgt is the key transcription factor and is the master regulator of human Th17 cells, a unique subset of CD4+T cells.

Arrien Pharmaceuticals applying its proprietary “Fragment-Field Drug Design” (FFDD) technology to identify novel, Med-Chem tractable hits into high ligand efficient leads derived from core scaffold binding patterns with in the target protein active site hot-spots